Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Samsung Group Set To Enter Biosimilars Market With $1.9 Billion Investment

This article was originally published in The Pink Sheet Daily

Executive Summary

Samsung Group says biosimilar and device moves are part of larger plan to invest $20.6 billion in five new business sectors by 2020.

You may also be interested in...



Korea's Samsung Electronics On Manhunt For Biosimilar Talent As Local Companies Keep Wary Eye On Competition

SEOUL - South Korea's leading biosimilar companies such as LG Life Sciences, Celltrion and others are increasingly wary of Samsung Electronics' ongoing talent search for research and development experts as the company prepares to make its debut in the blooming biosimilar business

Korea Moves To Help Samsung Electronics Create Consortium in Biosimilars

SEOUL - As the South Korean government accelerates its drive to get local producers of biosimilars globally competitive, the Ministry of Knowledge Economy is setting the stage for Samsung Electronics to become a giant in the emerging biosimlars market

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel